Open Collections

UBC Faculty Research and Publications

Clinical implications of recent key therapeutic trials Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 65 interprets the results and clinical implications of four recent key clinical trials. Conclusions: Torcetrapib increases mortality as compared to placebo in patients at high risk of coronary artery disease. Percutaneous coronary intervention (PCI) does not reduce mortality or cardiovascular serious adverse events as compared to no intervention as an initial management strategy in patients with stable angina due to coronary artery disease. Eicosapentaenoic acid (EPA) for hypercholesterolemia does not affect mortality as compared to placebo in a Japanese primary and secondary prevention population. Adding an oral anticoagulant to an antiplatelet increases life threatening bleeds and does not affect mortality or cardiovascular serious adverse events as compared to an antiplatelet alone in patients with peripheral vascular disease.

Item Metadata

Title
Clinical implications of recent key therapeutic trials
Alternate Title
Therapeutics Letter 65
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2007-08
Description
Therapeutics Letter 65 interprets the results and clinical implications of four recent key clinical trials. Conclusions: Torcetrapib increases mortality as compared to placebo in patients at high risk of coronary artery disease. Percutaneous coronary intervention (PCI) does not reduce mortality or cardiovascular serious adverse events as compared to no intervention as an initial management strategy in patients with stable angina due to coronary artery disease. Eicosapentaenoic acid (EPA) for hypercholesterolemia does not affect mortality as compared to placebo in a Japanese primary and secondary prevention population. Adding an oral anticoagulant to an antiplatelet increases life threatening bleeds and does not affect mortality or cardiovascular serious adverse events as compared to an antiplatelet alone in patients with peripheral vascular disease.
Subject
Angina, Stable; Anticoagulants; Coronary Artery Disease; Eicosapentaenoic Acid; Hypercholesterolemia; Percutaneous Coronary Intervention; Peripheral Vascular Diseases; Torcetrapib
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433644
URI
http://hdl.handle.net/2429/85054
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International